Cargando…
DNT Cell-based Immunotherapy: Progress and Applications
Cancer immunotherapy has firmly established a dominant status in recent years. Adoptive cellular immunotherapy (ACI) is the main branch of immunotherapy. Recently, the immune effector cells of ACI, such as T cells, NK cells, and genetically engineered cells, have been used to achieve significant cli...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171494/ https://www.ncbi.nlm.nih.gov/pubmed/32328176 http://dx.doi.org/10.7150/jca.39717 |
_version_ | 1783524082324602880 |
---|---|
author | Li, Yingrui Dong, Kang Fan, Xueke Xie, Jun Wang, Miao Fu, Songtao Li, Qin |
author_facet | Li, Yingrui Dong, Kang Fan, Xueke Xie, Jun Wang, Miao Fu, Songtao Li, Qin |
author_sort | Li, Yingrui |
collection | PubMed |
description | Cancer immunotherapy has firmly established a dominant status in recent years. Adoptive cellular immunotherapy (ACI) is the main branch of immunotherapy. Recently, the immune effector cells of ACI, such as T cells, NK cells, and genetically engineered cells, have been used to achieve significant clinical benefits in the treatment of malignant tumors. However, the clinical applications have limitations, including toxicity, unexpectedly low efficiency, high costs and strict technical requirements. More exploration is needed to optimize ACI for cancer patients. CD3+CD4-CD8- double negative T cells (DNTs) have emerged as functional antitumor effector cells, according to the definition of adoptive immunotherapy. They constitute a kind of T cell subset that mediates nontumor antigen-restricted immunity and has important immune regulatory functions. Preclinical experiments showed that DNTs had a dual effect by killing tumor cells and inhibiting graft-versus-host disease. Notably, DNTs can be acquired from healthy donors and expanded in vitro; thus, allogeneic DNTs may be provided as “off-the-shelf” cellular products that can be readily available for direct clinical application. We review the progress and application of DNTs in immunotherapy. DNTs may provide some novel perspectives on cancer immunotherapy. |
format | Online Article Text |
id | pubmed-7171494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-71714942020-04-23 DNT Cell-based Immunotherapy: Progress and Applications Li, Yingrui Dong, Kang Fan, Xueke Xie, Jun Wang, Miao Fu, Songtao Li, Qin J Cancer Review Cancer immunotherapy has firmly established a dominant status in recent years. Adoptive cellular immunotherapy (ACI) is the main branch of immunotherapy. Recently, the immune effector cells of ACI, such as T cells, NK cells, and genetically engineered cells, have been used to achieve significant clinical benefits in the treatment of malignant tumors. However, the clinical applications have limitations, including toxicity, unexpectedly low efficiency, high costs and strict technical requirements. More exploration is needed to optimize ACI for cancer patients. CD3+CD4-CD8- double negative T cells (DNTs) have emerged as functional antitumor effector cells, according to the definition of adoptive immunotherapy. They constitute a kind of T cell subset that mediates nontumor antigen-restricted immunity and has important immune regulatory functions. Preclinical experiments showed that DNTs had a dual effect by killing tumor cells and inhibiting graft-versus-host disease. Notably, DNTs can be acquired from healthy donors and expanded in vitro; thus, allogeneic DNTs may be provided as “off-the-shelf” cellular products that can be readily available for direct clinical application. We review the progress and application of DNTs in immunotherapy. DNTs may provide some novel perspectives on cancer immunotherapy. Ivyspring International Publisher 2020-03-31 /pmc/articles/PMC7171494/ /pubmed/32328176 http://dx.doi.org/10.7150/jca.39717 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Li, Yingrui Dong, Kang Fan, Xueke Xie, Jun Wang, Miao Fu, Songtao Li, Qin DNT Cell-based Immunotherapy: Progress and Applications |
title | DNT Cell-based Immunotherapy: Progress and Applications |
title_full | DNT Cell-based Immunotherapy: Progress and Applications |
title_fullStr | DNT Cell-based Immunotherapy: Progress and Applications |
title_full_unstemmed | DNT Cell-based Immunotherapy: Progress and Applications |
title_short | DNT Cell-based Immunotherapy: Progress and Applications |
title_sort | dnt cell-based immunotherapy: progress and applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171494/ https://www.ncbi.nlm.nih.gov/pubmed/32328176 http://dx.doi.org/10.7150/jca.39717 |
work_keys_str_mv | AT liyingrui dntcellbasedimmunotherapyprogressandapplications AT dongkang dntcellbasedimmunotherapyprogressandapplications AT fanxueke dntcellbasedimmunotherapyprogressandapplications AT xiejun dntcellbasedimmunotherapyprogressandapplications AT wangmiao dntcellbasedimmunotherapyprogressandapplications AT fusongtao dntcellbasedimmunotherapyprogressandapplications AT liqin dntcellbasedimmunotherapyprogressandapplications |